15.57 0.13 (0.84%) | 03-27 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 19.48 | 1-year : | 22.21 |
Resists | First : | 16.68 | Second : | 19.01 |
Pivot price | 15.76 | |||
Supports | First : | 12.89 | Second : | 10.73 |
MAs | MA(5) : | 15.48 | MA(20) : | 16.29 |
MA(100) : | 15.19 | MA(250) : | 16.79 | |
MACD | MACD : | -0.1 | Signal : | 0 |
%K %D | K(14,3) : | 23.4 | D(3) : | 22.5 |
RSI | RSI(14): 48.6 | |||
52-week | High : | 35.66 | Low : | 6.46 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TGTX ] has closed above bottom band by 43.4%. Bollinger Bands are 43.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 15.63 - 15.7 | 15.7 - 15.77 |
Low: | 14.87 - 14.95 | 14.95 - 15.03 |
Close: | 15.43 - 15.56 | 15.56 - 15.69 |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Wed, 27 Mar 2024
Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock? - Yahoo Movies Canada
Wed, 27 Mar 2024
Brookstone Capital Management Sells 688 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
Mon, 25 Mar 2024
TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet - Simply Wall St
Tue, 19 Mar 2024
Is TG Therapeutics, Inc.'s (NASDAQ:TGTX) Recent Price Movement Underpinned By Its Weak Fundamentals? - Yahoo Finance
Fri, 08 Mar 2024
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the ... - Yahoo Finance
Fri, 01 Mar 2024
Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Simply Wall St
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 154 (M) |
Held by Insiders | 1.3488e+008 (%) |
Held by Institutions | 9 (%) |
Shares Short | 29,120 (K) |
Shares Short P.Month | 0 (K) |
EPS | 2.084e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 5.4 % |
Operating Margin | -28.4 % |
Return on Assets (ttm) | 4.9 % |
Return on Equity (ttm) | 11.5 % |
Qtrly Rev. Growth | 54 % |
Gross Profit (p.s.) | 370.72 |
Sales Per Share | 1.00283e+008 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -31 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | 32.1 |
Dividend | 0 |
Forward Dividend | 3.484e+007 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |